公开(公告)号：US12065438B2

公开(公告)日：2024-08-20

申请号：US17289062

申请日：2019-11-01

申请人： Merck Sharp & Dohme LLC

发明人： Yongxin Han ,  David Jonathan Bennett ,  Indu Bharathan ,  Liangqin Guo ,  Brett A. Hopkins ,  Xianhai Huang ,  Derun Li ,  Min Lu ,  Alexander Pasternak ,  David L. Sloman ,  Hongjun Zhang ,  Hua Zhou

IPC分类号： C07D471/04 ,  C07D209/94 ,  C07D215/14 ,  C07D401/04 ,  C07D403/04

CPC分类号： C07D471/04 ,  C07D209/94 ,  C07D215/14 ,  C07D401/04 ,  C07D403/04

摘要： Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20230303540A1

公开(公告)日：2023-09-28

申请号：US18041849

申请日：2021-09-01

申请人： Merck Sharp & Dohme LLC

发明人： John J. Acton, III ,  Ryan Chau ,  Peter H. Fuller ,  Anmol Gulati ,  Rebecca Elizabeth Johnson ,  Solomon Kattar ,  Mitchell H. Keylor ,  Derun Li ,  Kaila A. Margrey ,  Gregori J. Morriello ,  Xin Yan

IPC分类号： C07D405/14 ,  C07D403/14 ,  C07D491/107 ,  C07D487/10 ,  C07D403/12 ,  C07D487/04 ,  C07D471/08 ,  C07D498/08 ,  C07D417/14

CPC分类号： C07D405/14 ,  C07D403/14 ,  C07D491/107 ,  C07D487/10 ,  C07D403/12 ,  C07D487/04 ,  C07D471/08 ,  C07D498/08 ,  C07D417/14

摘要： The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

公开(公告)号：US12030872B2

公开(公告)日：2024-07-09

申请号：US17286870

申请日：2019-10-25

申请人： Merck Sharp & Dohme LLC

发明人： Vladimir Simov ,  William P. Kaplan ,  John J. Acton, III ,  Michael J. Ardolino ,  Joanna L Chen ,  Peter H. Fuller ,  Hakan Gunaydin ,  Derun Li ,  Ping Liu ,  Kaitlyn Marie Logan ,  Joey Methot ,  Gregori J. Morriello ,  Santhosh F. Neelamkavil ,  Luis Torres ,  Xin Yan ,  Hua Zhou

IPC分类号： C07D405/14 ,  C07D401/14 ,  C07D403/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

CPC分类号： C07D405/14 ,  C07D401/14 ,  C07D403/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

摘要： The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

公开(公告)号：US20230140132A1

公开(公告)日：2023-05-04

申请号：US17789374

申请日：2020-12-18

申请人： MERCK SHARP & DOHME LLC

发明人： Abdelghani Abe Achab ,  Matthew L. Childers ,  Christian Fischer ,  Symon Gathiaka ,  Derun Li ,  Min Lu ,  Anandan Palani ,  Rachel L. Palte ,  Qinglin Pu ,  David L. Sloman ,  Hongjun Zhang

IPC分类号： C07F5/02

摘要： Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.